Loading stock data…
NVAX
$8.03-0.01 (-0.12%)
Market ClosedLast close May 4
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novavax, Inc. in the Healthcare sector is trading at $8.03. The stock is currently 33% below its 52-week high of $11.97, remaining 2.1% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why NVAX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.03
Potential Downside
1571.5%
Whystock Fair Value$-118.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$14.00+74.4%
Range$7.00 – $25.00
Fundamentals
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.38B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.28
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-330.97%
Volume
Today's trading volume
3.41M
Recent News
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
A Look At Novavax (NVAX) Valuation As It Shifts To Licensing And Awaits Combo Vaccine Data
Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo readout. See our latest analysis for Novavax. The licensing pivot and upcoming COVID influenza combo catalyst come after a mixed period for investors, with a 12.76% year-to-date share price return alongside a 25.43% one-year total shareholder return, but a very large five-year total shareholder loss...
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Novavax (NVAX) concluded the recent trading session at $8.01, signifying a +1.01% move from its prior day's close.
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now?
Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.’s share was trading at $8.67 as of April 20th. NVAX’s trailing P/E was 3.36 according to Yahoo Finance. Novavax, Inc., a biotechnology company, engages in the discovery, development, […]
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.